Research programme: RNAi therapeutics - Alnylam/Arrowhead Pharmaceuticals

Drug Profile

Research programme: RNAi therapeutics - Alnylam/Arrowhead Pharmaceuticals

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Arrowhead Research Corporation
  • Developer Alnylam Pharmaceuticals; Arrowhead Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria
  • Research Cancer; Hepatitis B; Liver disorders; Metabolic disorders; Respiratory tract disorders

Most Recent Events

  • 06 Apr 2016 Arrowhead Research Corporation is now called Arrowhead Pharmaceuticals
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 15 Mar 2012 RNAi therapeutics are still in preclinical development for Cancer, respiratory disorders, metabolic disorders, liver disorders and malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top